Rhythm Pharmaceuticals (RYTM) said Wednesday it has modified phase 2 and 3 trials evaluating its setmelanotide medicine for rare genetic diseases of obesity to focus on rare patient populations that it believes "have the highest likelihood of success."
The modifications, which follow recent feedback from the US Food and Drug Administration, and a streamlining of its planned clinical trial sites network are expected to generate "meaningful cost savings," Rhythm said. The modifications include the elimination of a fifth sub-study in the phase 3 Emanate trial, leaving it with four independent sub-studies.
The company now expects that its existing cash, cash equivalents and short-term investments will be adequate to finance operations into at least Q4 of next year.
The stock was down more than 17% in afternoon trading amid a broadly lower market.
Price: 9.67, Change: -2.04, Percent Change: -17.42
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|